Streetbeat News

Revenues

CHD

Church & Dwight shares rose following the release of strong Q3 financial results and an increase in FY24 net sales guidance.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 7:19 pm

TEVA

Teva Pharmaceuticals presented new data at the Psych Congress 2024 from the IMPACT-TD Registry, highlighting differences in tardive dyskinesia (TD) patient experiences based on psychiatric conditions. The study found fewer TD diagnoses in patients with psychotic disorders compared to those with mood disorders. Teva continues to innovate in mental health treatment with AUSTEDO® XR® and AUSTEDO tablets.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 7:18 pm

HMC

American Honda reported a 32.6% increase in sales for October, reaching 108,088 units, despite supply constraints. The Honda brand saw a 33.9% rise in sales, with a balanced mix of passenger cars and light trucks. Electrified vehicle sales accounted for a quarter of Honda's total sales in 2023.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 7:05 pm

SUM

In the past three months, 13 analysts have rated Summit Materials (NYSE:SUM), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 3.04% to $49.46. Analysts have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. Summit Materials has shown a revenue growth rate of 4.73% but faces challenges with net margin, ROE, ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 7:00 pm

AGIO

Analysts have mixed views on Alnylam Pharmaceuticals (NASDAQ:AGIO) with recent ratings showing a shift towards somewhat bullish sentiments. The average 12-month price target has decreased by 3.17% to $53.5. Despite positive revenue growth, the company faces challenges with profitability and returns.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 7:00 pm

VIAV

Viavi Solutions (NASDAQ:VIAV) has received mixed analyst ratings over the past three months, with a recent positive shift in average price targets. Analysts have raised and lowered ratings, reflecting diverse perspectives on the company's performance. Viavi faces challenges with declining revenue, low net margins, and below-average returns on equity and assets. However, it maintains a balanced debt approach.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 7:00 pm

CLX

Over the past three months, 9 analysts have shared their insights on Clorox (NYSE:CLX), with opinions ranging from bullish to bearish. The average 12-month price target has increased by 6.09% to $154.89. Clorox has shown a 27.13% revenue growth rate, but faces challenges with a low net margin and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 7:00 pm

OPCH

Option Care Health (NASDAQ:OPCH) has received mixed analyst ratings over the past three months, with a shift towards more bullish sentiments recently. Analysts have lowered their 12-month price targets, with an average target of $33.8, down from $39.00. Despite this, the company shows strong financial performance with significant revenue growth, high net margins, and efficient debt management.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 7:00 pm

TM

Toyota Motor North America reported a 5% decrease in U.S. vehicle sales for October, with a total of 185,929 vehicles sold.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 6:56 pm

ESNT

Essent Group's shares declined following the release of disappointing Q3 earnings and revenue figures.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 6:55 pm